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Background: Increasing numbers of immunocompromised patients have resulted in greater incidence of
invasive fungal infections with high mortality. Candida albicans infections dominate, but during the last
decade, Candida glabrata has become the second highest cause of candidemia in the United States and
Northern Europe. Reliable and early diagnosis, together with appropriate choice of antifungal treatment, is
needed to combat these challenging infections.
Objectives: To confirm the identity of 183 Candida glabrata isolates from different human body sites using
matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) and VITEK†2, and to analyze
isolate protein profiles and antifungal susceptibility. The minimum inhibitory concentration (MIC) of seven
antifungal drugs was determined for the isolates to elucidate susceptibility.
Design: A total of 183 C. glabrata isolates obtained between 2002 and 2012 from Norwegian health-care units
were analyzed. For species verification and differentiation, biochemical characterization (VITEK†2) and mass
spectrometry (MALDITOF) were used. MIC determination for seven antifungal drugs was undertaken using
E-tests†.
Results: Using VITEK†2, 92.9% of isolates were identified as C. glabrata, while all isolates (100%) were
identified as C. glabrata using MALDI-TOF. Variation in protein spectra occurred for all identified C. glabrata
isolates. The majority of isolates had low MICs to amphotericin B (51 mg/L for 99.5%) and anidulafungin
(50.06 mg/L for 98.9%). For fluconazole, 18% of isolates had MICs 32 mg/L and 82% had MICs in the range
]0.016 mg/L to 532 mg/L.
Conclusions: Protein profiles and antifungal susceptibility characteristics of the C. glabrata isolates were diverse.
Clustering of protein profiles indicated that many azole resistant isolates were closely related. In most cases,
isolates had highest susceptibility to amphotericin B and anidulafungin. The results confirmed previous
observations of high MICs to fluconazole and flucytosine. MALDI-TOF was more definitive than VITEK†2
for C. glabrata identification.
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I
n healthy humans, yeasts are part of the commensal
microbiota. However, these yeast species can act as
opportunistic pathogens at different parts of the
body, including the oral cavity. Patients with a reduced
immune response, experiencing surgical procedures, with
a reduced blood supply, in receipt of broad-spectrum
antibiotics or immune suppressing medication, are at risk
of opportunistic fungal infections. Associated with the
expanding elderly population there has been an increase
in severe systemic fungal infections (13). Such infections
result in increased morbidity and mortality as well as
high costs to society. Hospital infections caused by differ-
ent Candida species can result in up to 30 extra hospital
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Candida infections is in the range 571% (5). Thus, it is
highly important to prevent and treat these infections,
including those of the oral cavity. Candida albicans is the
predominant cause of fungal infection in humans. Based
on the data from global epidemiological studies, signifi-
cant geographical variation is evident (68), both in
incidence and response of C. glabrata to antifungal drugs.
Several reports indicate that C. glabrata infections have
increased and are now the second most prevalent cause of
candidosis (3, 810), although this can vary with age,
gender (8), and geographical location. Data from the
ARTEMIS Antifungal Surveillance Program between
2001 and 2007 showed that C. glabrata accounted for
11.6% of Candida isolated from all body sites, with a
frequency ranging from 7.4% in Latin America to 21.1%
in North America (7).
Infection with C. glabrata is also a concern because of
the reduced antifungal susceptibility of this species,
especially to azoles (1, 3, 7, 8). An increasing number of
studies report that C. glabrata and other Candida species
also develop resistance to echinocandins (1114) and co-
resistance to both azoles and echinocandins has been
found in bloodstream infection isolates (11). Rapid and
precise testing procedures for species identification with
reliable prediction of antifungal resistance patterns are
essential in making appropriate treatment decisions. The
use of matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry (MALDI-TOF MS) requires
only 1 h of analysis and is increasingly being adopted as
a time-saving diagnostic to supplement conventional
identification methods such as morphological and bio-
chemical approaches.
The aims of the present study were twofold and were to
confirm identity of the test isolates using MALDI-TOF
and the VITEK†2 (BioMérieux, Inc., Durham, NC, USA)
system, and also compare isolate diversity in terms of
protein profiles and antifungal susceptibility patterns. The
C. glabrata isolates were from different human sites,
namely the oral cavity and gastrointestinal tract (OGI
tract), respiratory tract (R tract), and blood. Susceptibility
testing and minimum inhibitory concentration (MIC)
determination to seven different antifungal drugs was
performed to assess associated resistance.
Materials and methods
Clinical isolates and reference strains
A total of 183 C. glabrata isolates from the Microbiological
Diagnostic Service (Department of Oral Biology (DOB),
Faculty of Dentistry, University of Oslo, Norway) and
the Norwegian Mycological Reference Laboratory (De-
partment of Microbiology, Oslo University Hospital,
Rikshospitalet, University of Oslo (OUS), Norway) were
included in the study. These isolates were collected between
2003 and 2011 from patients attending different Norwegian
health-care units. All isolates had previously been defini-
tively identified as C. glabrata using routine identification
methods at the time of isolation. Fifteen isolates originated
from the OGI tract, 17 from the respiratory tract, 150 from
blood, and one was of unknown origin. The distribution of
isolates in patients and their site of isolation are presented
in Table 1. Four different Candida reference strains from the
American Type Culture Collection (ATCC†) (C. glabrata
ATCC-15545D-5TM, C. parapsilosis ATCC-22019D-5TM, C.
albicans ATCC-90028D-5TM and C. dubliniensis ATCC-
MYA-646TM) were included as controls. The Norwegian
Institute of Public Health provided a single reference strain
of C. glabrata. Isolates were cultured from frozen stocks on
to CHROMagar† Candida (Paris, France) and incuba-
ted aerobically for 48 h at 378C. One single colony was re-
cultivated from each plate for subsequent testing.
Biochemical identification
Biochemical identification was based on assessing carbon
and nitrogen assimilation and enzymatic activities. The
yeast identification card in the VITEK†2 (BioMérieux)
system includes 46 biochemical tests and can identify up to
50 different yeast species within 18 h by comparison with
an integrated database (BioMérieux Clinical Diagnostics
website, April 2012, June 2014). Identification is catego-
rized as: ‘Excellent’ (9699%), ‘Very Good’ (9395%),
‘Good’ (8992%), ‘Acceptable’ (8588%), ‘Low Discrimi-
nation’, and ‘Inconclusive’. These categories are defined by
numbers of possibilities. If two possible identities exist, the
result is presented as below ‘Acceptable’, ‘Low Discrimina-
tion’ represents 23 options and ‘Inconclusive’ 3 op-
tions. When identity scores were below ‘Acceptable’, the
sample was retested. Preparation and analyses of isolates
were performed according to the manufacturer’s instruc-
tions. All isolates had previously been definitively identi-
fied as C. glabrata according to routine identification
methods used in clinical microbiology laboratories.
The identity of isolates that led to a low-discrimination
level result was subsequently confirmed by 18S rRNA
sequencing.
Protein profiling
All isolates were subcultured from CHROMagar† Candida
by inoculating one single colony on Sabouraud dextrose
agar, which was incubated aerobically for 24 h at 378C.
Prior to MALDI-TOF MS analysis, an ethanol/formic
acid extraction procedure was performed according to the
manufacturer’s instructions (Bruker Daltonics, GmbH,
Bremen, Germany). All isolates were analyzed in duplicate
using high-performance liquid chromatography (HPLC)
quality reagents throughout. Briefly, using a 10-mL inocu-
lation loop, a colony of 24-h yeast culture was transferred
to 300 mL of sterile water (HPLC-quality) in a 1.5-ml
Eppendorf Safe Lock TubeTM, and suspended and mixed
with 900 mL of absolute ethanol. After centrifugation
(13,000 rpm for 2 min, Heraeus† Megafuge† 1.0), the
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Table 1. Origin of the 183 investigated C. glabrata isolates including reference strains in the 10 clusters in the protein profile
cluster dendrogram
Cluster no. Protein profile no. Strain Source Azole resistance
43 C. albicans
48 C. albicans
2 C. albicans, ATCC† 90028D-5TM
4 C. dubliniensis, ATCC† MYA-646TM
123 C. tropicalis
1 C. parapsilosis, ATCC† 22019D-5TM
5 E. coli
11 C. glabrata clinical isolate Blood
17 C. glabrata clinical isolate R tract VO
1 49 C. glabrata clinical isolate R tract VO
51 C. glabrata clinical isolate R tract FL, VO
58 C. glabrata clinical isolate R tract FL, VO
171 C. glabrata clinical isolate Blood FL, VO
54 C. glabrata clinical isolate Bi
55 C. glabrata clinical isolate OGI tract
191 C. glabrata clinical isolate Blood
170 C. glabrata clinical isolate OGI tract VO
50 C. glabrata clinical isolate R tract FL, VO
56 C. glabrata clinical isolate Blood
169 C. glabrata clinical isolate Blood VO
179 C. glabrata clinical isolate Blood
165 C. glabrata clinical isolate Blood VO
2 3 C. glabrata, ATCC† 15545D-5TM
C. glabrata clinical isolates (n16) FL (3), VO (12)
3 C. glabrata clinical isolates (n48) FL (3), VO (7)
4 C. glabrata clinical isolates (n13) FL (9), VO (29)
5 C. glabrata clinical isolates (n2) FL (4), VO (9)
6 C. glabrata clinical isolates (n14)
7 C. glabrata clinical isolates (n40) FL (6), VO (30)
8 C. glabrata clinical isolates (n5) FL (1), VO (5)
9 C. glabrata clinical isolates (n15) FL (2), VO (5)
13 C. glabrata clinical isolate Blood FL, VO
24 C. glabrata clinical isolate Blood VO
31 C. glabrata clinical isolate Blood FL, VO
32 C. glabrata clinical isolate Blood FL, VO
30 C. glabrata clinical isolate R tract
35 C. glabrata clinical isolate OGI tract
16 C. glabrata clinical isolate Blood FL, VO
10 29 C. glabrata clinical isolate Blood FL, VO
36 C. glabrata clinical isolate OGI tract FL, VO
37 C. glabrata clinical isolate OGI tract
18 C. glabrata clinical isolate R tract VO
20 C. glabrata clinical isolate Blood FL, VO
25 C. glabrata clinical isolate R tract VO
26 C. glabrata clinical isolate Blood FL, VO
34 C. glabrata clinical isolate OGI tract FL, VO
Protein profile numbers refer to identification by the MALDI-TOF MS analysis, see results section. Blood isolates (n150). Isolates from
other sources than blood (n33) includes: OGI tract (oral cavity and gastro intestinal tract; n15), R (respiratory) tract (n17), and Bi
(biopsy) from an unknown site (n1). Azole resistance: MICs32 mg/L toward fluconazole (FL) and MICs0.125 toward voriconazole
(VO). Number of resistant isolates in parentheses.
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supernatant was removed. Centrifugation was repeated
and the resulting pellet dried for 2 min at room temperature
before re-suspension in 50 mL of 70% (v/v) formic acid and
mixing with 50 mL acetonitrile. The sample was centrifuged
(13,000 rpm for 2 min, Heraeus† Megafuge† 1.0) and 1 mL
of supernatant placed on the target plate. The sample was
dried at room temperature before being covered with 1 mL
of matrix (a-cyano-4-hydroxy-cinnamic acid (HCCA),
Bruker Daltonics) and air-dried again. The HCCA matrix,
10 mg, was dissolved in 250 mL of organic solution
(trifluoroacetic acid (TFA) 2.5%, acetonitrile 50%, and
water 47.5%) by vortex mixing at room temperature.
Reference strains were included as positive controls in all
analyses. In accordance with the manufacturer’s protocol,
an Escherichia coli standard (Bruker Bacterial Test
Standard (BTS), Bruker Daltonics) was included. This
bacterial standard is ‘spiked’ with two additional high
molecular weight proteins, enabling calibration across the
entire mass range (417 kDa) of proteins used for
identification of microorganisms (www.bruker.com).
Bioinformatic analysis was performed with the integrated
MALDI Biotyper 3.0 software, which compared the mass
spectra from the samples to profiles stored in the reference
library. Results of pattern matching were presented as log
score values in the range 03. According to the manufac-
turer’s guidelines, a score of 2.33.0 gives a highly probable
species identification, while scores between 2.0 and 2.299
provide confidence to genus level and probable species
identification (Bruker Daltonics MALDI Biotyper 3.1).
For C. glabrata, a log score of 2.0 was chosen for species
identification at OUS. When scores were below 2.0,
samples were retested, and the spectra from each isolate
with the two best matches (2.0 or above) chosen.
Clustering and correlation analysis of protein spectra
The heterogeneity of the raw protein-spectrum set was
analyzed by the MALDI Biotyper managed by an external
MATLAB software tool, integrated in the equipment.
Results were visualized in a clustering dendrogram (Fig. 1),
representing the closeness of individual spectra (the x-axis
as protein profile numbers) to one another. Composite
correlation index (CCI) analysis is a statistical tool of the
MALDI Biotyper to visualize the similarity between
protein spectra in a heat map. A composition of correla-
tions of all the intervals provides the CCI. In the heat map
grid, the different colors of the squares at the intersection
of two fungal colonies (in the diagram called ‘groups’)
indicate their relationship. Dark red represents a close
relation, whilst blue are more distantly related (Bruker
Daltonics MALDI Biotyper 3.1 User Manual Revision 1).
The clustering and correlation analysis of protein spectra
was achieved using Maldi Biotyper Compass version 4.1.
MIC determination/testing
MIC determination or testing was done using E-tests†
(BioMérieux) as recommended by the manufacturer.
Fig. 1. Protein profile cluster (Principal Component Analysis (PCA)) dendrogram of the 183 C. glabrata and reference strains
grouped into 10 clusters based on proteomic profiling. The clusters are marked by color and numbered 110 (Maldi Biotyper
Compass version 4.1).
Kari-Mette Andersen et al.
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The E-test† is a fast and cost-effective alternative to
‘gold standard’ procedures developed by the Clinical and
Laboratory Standards Institute (CLSI) (15) and the
European Committee on Antimicrobial Susceptibility
Testing (EUCAST) (16). The agreement between both
methods is considered high (17).
Susceptibility of all 183 isolates to amphotericin B
(polyene), fluconazole, and voriconazole was determined.
The susceptibility of 179 isolates was established to
anidulafungin, 146 isolates to caspofungin, 71 isolates to
micafungin and 36 isolates to flucytosine (nucleoside
analog). The E-test† was applied to inoculated agar and
incubated at 358C for 48 h. MICs for amphotericin B were
determined as the lowest concentration of antifungal agent
inhibiting any growth. For azoles and echinocandins, 80%
reduction of growth represented the MIC. Flucytosine
MICs were determined as the lowest concentrations that
caused a 90% reduction in growth. Reading and inter-
pretation of the results were in accordance with the
manufacturer and procedures of the Norwegian Mycolo-
gical Reference Laboratory (OUS), which is based on
recommended breakpoints (BPs, mg/L) given by EUCAST
(www.eucast.org. 2015).
Clinical BPs
The BPs for susceptibility testing are regularly revisited and
re-established according to shifts in clinical relevance, epi-
demiological differences, and available antimicrobials. New
recommended BPs were given for amphotericin B, flucona-
zole, anidulafungin, and micafungin in 2014 by EUCAST
(Table 2). There are no established European BPs for
caspofungin, voriconazole, or flucytosine. Isolates suscep-
tible to anidulafungin as well as micafungin were consi-
dered susceptible to caspofungin (www.eucast.org. 2015).
Results
Culture and purification
Colonies of all isolates appeared white on CHROMagar†
Candida corresponding to the C. glabrata control strains
included in the study.
Table 2. Antimicrobial susceptibility of C. glabrata to five of the antifungals tested
MIC (mg/L)
Proportion of all isolates (%)
MIC (mg/L)
Proportion of blood isolates (%)
MIC (mg/L)
Proportion of other isolates (%)

























































































NORM 2012  results (n23) in italic/bold. Susceptible (S), intermediate susceptible (I), and resistant (R) according to the recommended
breakpoints (BPs, mg/L) given by the European Committee on Antimicrobial Susceptibility Testing  EUCAST in 2014.
*Due to insufficient evidence that C. glabrata is a good target for therapy with voriconazole, no EUCAST breakpoints were available in
2014, and BPs made for C. albicans, C. tropicalis, and C. parapsilosis were used.
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Biochemical identification
Identification using biochemical analysis (VITEK†2)
showed that 170 of the 183 (92.9%) isolates had a dis-
crimination confidence level compatible with C. glabrata.
A ‘Low discrimination’ score was obtained for 13 strains,
with two (15.4%) originating from the gut and 11 (84.6%)
from blood. Isolates with a low identity score were verified
by 18S rRNA sequencing. The five most common positive
biochemical tests were: D-glucose assimilation (dGLUa)
and Leucine-Arylamidase (LeuA) (positive for 100%
isolates), D-mannose assimilation (dMNEa) (positive for
99.5% isolates), D-trehalose assimilation (dTREa) (posi-
tive in 93.4%), and acetate assimilation (ACEa) (positive
for 92.9% isolates). All isolates with a ‘Low discrimination’
score were negative for the ACEa test, and one of these
isolates was positive in the dTREa test. The identification
messages, confidence levels, and source distribution are
listed in Supplementary file.
Protein profiling
All isolates were identified as C. glabrata using the
MALDI-TOF MS, with a log score 2.0 or above. In the
clustering and correlation analysis, all protein spectra
were sorted by group numbers as protein profile numbers
(different from isolate numbers) by the software program
(Maldi Biotyper Compass version 4.1) (Fig. 1).
Clustering and correlation analysis of protein spectra
The protein profile dendrogram distributed the protein
spectra into 10 clusters (Fig. 1 and Table 1). An enlarged
view of cluster 1 is presented in Supplementary file. This
cluster contained two subclusters: the first covered all
seven reference/quality controls from other species, and the
second subcluster contained 15 clinical C. glabrata isolates
(Supplementary Fig. 2). Cluster number 210 included
clinical C. glabrata isolates. The C. glabrata reference
strain (ATCC†15545D-5TM) was placed in cluster 2.
Results from the CCI analysis were presented as a heat
map grid in which all the non-C. glabrata controls and
reference strains were indicated by dark blue lines in the
diagram, demonstrating no relationship to the C. glabrata
isolates. For the C. glabrata group, most were expressed by
different shades of red, orange, and yellow, indicating close
relationships. All intersections of identical groups were
represented by a dark red color making a diagonal line in
the map grid (Fig. 2).
MIC determination
MIC testing revealed that 99.5% of isolates had MIC
values 51 mg/L for amphotericin B, and included 100% of
blood isolates and 97% of other isolates. For fluconazole,
82% of isolates MICs in the range ]0.02 mg/L to532 mg/L,
and 18% had MICs32 mg/L. There were fewer flu-
conazole resistant isolates from blood (14.7%) compared
with other sources (33.2%). None of the isolates were
totally susceptible to fluconazole. For voriconazole, 31.2%
of isolates had MICs50.125 mg/L (34% from blood,
18.1% of isolates from other sites), while 68.8% of isolates
had MICs0.125 mg/L (66% from blood, 81.9% of
isolates from other sites). For anidulafungin, MICs0.06
0.06 mg/L were recorded for 1.1% of isolates, leaving
almost all (98.9%) isolates susceptible to this agent. Blood
isolates were slightly less susceptible to this agent (98.6%
versus 100%). The only two isolates resistant to anidula-
fungin in the test (no. 20 and no. 99) were from blood, and
both were sensitive to amphotericin B (MIC, 0.125 mg/L).
For the 71 isolates tested against micafungin, 98.6% had
MICs 50.032 mg/L, and the only resistant isolate (no. 20)
was also resistant to anidulafungin. Based on BPs made for
C. albicans, C. tropicalis, and C. parapsilosis, isolate no. 20
was susceptible to amphotericin B (MIC0.125 mg/L)
and voriconazole and had intermediate susceptibility
against fluconazole (MIC2 mg/L).
The MIC results from the five currently most used
antifungals are shown in Table 2, while results from all
the antifungal gradient agar diffusion tests (E-test†) are
presented in Supplementary file.
Discussion
C. glabrata infections have increased in recent decades and
are now the second most prevalent cause of candidemia in
the United States and Northern Europe (3, 810). A rapid
and reliable diagnosis of these infections, combined with
antifungal resistance determination, are needed, especially
when patients are critically ill.
Screening patient samples on CHROMagar† Candida
provides an initial presumptive identification of
Candida species. Colonies of certain clinically significant
Candida species exhibit different colors on this agar.
However, C. glabrata colonies appear white on this
medium, which is similar to some other species. After
screening, further analyses are therefore necessary to
definitively identify the Candida species.
The VITEK†2 provides a biochemical characterization
of the species of interest and is based on 46 biochemical
reactions and is capable of identifying up to 50 different
yeasts. In this study, the VITEK†2 identified 92.9% of
isolates as C. glabrata. All but one C. glabrata isolate tested
positive in the following three tests: dGLUa, LeuA, and
dMNEa. C. glabrata is claimed to ferment and assimilate
two sugars only, glucose and trehalose, and this is atypi-
cal for the majority of Candida species, which normally
demonstrate a wide repertoire for sugar utilization. Under
certain conditions, C. glabrata hydrolyzes trehalose into
glucose more rapidly than other species and on this basis,
several commercial tests have been developed specifically
for rapid and cost-effective presumptive identification of
C. glabrata (18). In our study, a ‘Low probability’ score
from the VITEK†2 system was obtained for 13 isolates, in
which one isolate was positive for the trehalose-assimilation-
test (dTREa). In contrast, whenever the ACEa test (ACEa)
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was negative, the probability score was ‘low’. Our re-
sults indicate that the specific ACEa test and not the
trehalose-assimilation test was crucial for identifica-
tion of C. glabrata. VITEK†2 is widely used in clinical
microbiology, but it is not able to identify all species despite
continuous update of the software database.
The second diagnostic tool used was MALDI-TOF MS.
All isolates were identified as C. glabratawith the MALDI-
TOF MS analysis. The score was ]2.0 for two of the
duplicate tests. Prior to analysis, a standard protein
extraction of the yeast isolates was performed and the
cutoff for species level was set to 2.0, according to the
manufacturer’s instructions and protocols at OUS. A
more uncomplicated and time-saving alternative would
be ‘on-plate extraction’ or ‘on-target lysis’ procedures and
eventually lowering the interpretative cutoff from 2.0
to 1.7 (19, 20), although this would not give the most
predictable results. Another way of reducing procedural
time might be to grow the yeasts in liquid media (21).
The dendrogram (Principal Component Analysis
(PCA) dendrogram) created from the acquired protein
profiles distributed the isolates into 10 clusters (Fig. 1).
Cluster no 1 contained two subclusters: the first of which
covered all seven reference/quality controls from other
species, and the second subcluster contained 15 clinical C.
glabrata isolates (Maldi Biotyper Compass version 4.1).
Cluster nos. 210 contained C. glabrata strains from
different sources, and all included blood isolates. The
two smaller clusters (nos. 5 and 8) included blood samples
only, but no cluster had samples only from the other
sources. Our results indicate little difference in protein
profiles between isolates according to their origin (source).
Due to a limited number of isolates of oral (n7) and
gastrointestinal tract (n8) origin compared with blood,
no conclusions can be drawn. All clinical C. glabrata
isolates assembled in cluster no 1 had ‘Excellent’ or ‘Very
Good’ identification in VITEK†2 analysis (Table 1). Eight
out of the 13 isolates with a ‘Low probability’ score were in
cluster no. 10 and had a different protein expression profile
from the other C. glabrata isolates. This observation may
associate with their antifungal resistance. All eight (seven
originating from blood and one from the gastrointestinal
tract) had high MICs for fluconazole and voriconazole.
CCI analysis illustrated diversity in protein expression.
In the heat map diagram, variation in color indicative of
variation in protein expression occurred with most isolates
grown under standardized conditions. All reference strains
were deemed to have distant relationships in terms of
their protein spectra to C. glabrata. For C. glabrata, most
isolates were represented as different shades of red, orange,
and yellow indicating close relationship between protein
spectra. However, some isolates also showed signs of
greater differences in protein spectra with blue and green
colors in some of the intersection squares (Fig. 2).
Correct and rapid species identification is crucial for
appropriate antifungal treatment. Despite the diversity in
protein spectra, MALDI-TOF MS seems, according to
our investigation, to be the most reliable and rapid
method (within 1 h), while the VITEK†2 results were
not available until the next day. These conclusions are in
accordance with those made by others (22).
MIC determination is of utmost importance in clinical
microbiology for in vitro susceptibility testing of the drugs
of choice. Almost all isolates in this study were susceptible
to amphotericin B (MIC51 mg/L in 99.5%), anidulafun-
gin (MIC50.06 mg/L in 98.9%), and micafungin (MIC5
0.032 mg/L in 98.6%). In recent decades, an increase in
echinocandin resistance among C. glabrata isolates has
been reported and has the order of 4.318.9% (11, 12, 14,
23). A review by Arendrup and Perlin (13) described
emerging resistance in America and resistance on a smaller
scale in Europe. In Denmark, echinocandin resistance
rates increased from zero in 20042007 to 0.9% in 2008
2009, 1.2% in 20102011 and 3.1% in 20122013 (13). Our
findings are in agreement with these recent values and
appear to follow the same resistance incidence as in
Denmark. The Norwegian annual reports from 2008 to
2013 provide a slightly different picture, showing zero
resistance in the first 3 years (2426), increasing to 8%
resistance in 2011, and declining to 4.3% in 2012 and to
zero resistance in 2013 (12, 23, 27).
Based on EUCAST-BPs from 2014, in this study, total
susceptibility to fluconazole was not evident for any
isolates, with 18% being resistant (MIC32 mg/L) and
82% intermediately susceptible (0.002 mg/L MIC 5 32
mg/L). Our results were in accordance with those from the
last two NORM reports (23, 27) as well as findings from
other countries where fluconazole resistance in C. glabrata
has been increasing from 5.6% in 19972007 (7) to 11.9% in
20082011 (28). Among isolates from blood, resistance to
fluconazole was 14.7% while the proportion was 33.2% for
other isolates.
Antifungal susceptibility and BPs as well as laboratory
procedures have changed over the years. In our study,
clinical blood isolates (n150) were collected between
2003 and 2011, while isolates in the different NORM
reports (nB40) were collected yearly (www.vetinst.no/nor/
Publikasjoner/NORM-NORM-VET). These differences
make comparison difficult.
For voriconazole, all isolates had MICs 532 mg/L,
indicating an in vitro activity superior to fluconazole, a
result in accordance with findings elsewhere (29). How-
ever, cross-resistance between fluconazole and voricona-
zole is frequently seen, especially with C. glabrata (11,
30). Due to insufficient evidence that C. glabrata is a
good target for therapy with voriconazole, no European
BPs are available, and clinical interpretations have
not been made. Considering the BPs for C. albicans,
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C. tropicalis, and C. parapsilosis, 68.8% of the isolates
would be regarded as resistant to voriconazole.
C. glabrata isolates with high MICs toward the triazoles
were represented in all protein profile clusters; however,
cluster no. 10 had a higher representation. This cluster (no.
10) contained 15 isolates (eight from blood, four from OGI
tract, three from R tract), 12 having high MICs to vori-
conazole and 9 to fluconazole. Eight of the 13 isolates,
which had low identity scores in the VITEK†2 test, were in
cluster 10, and all of them were simultaneously resistant to
both triazoles tested (MIC32 mg/L to fluconazole,
MIC0.125 mg/L to voriconazole). It would be interest-
ing to further investigate the relationship between the
resistance and protein cluster profiles.
Primary resistance to flucytosine (5-fluorocytosine) is
reported as low (212%) for Candida (31), although higher
for some species such as C. krusei (28% R) (32) and C.
glabrata (18% R) (31). The frequent development of
flucytosine resistance has led to limited use as a mono-
therapy and is mainly utilized in combination with ampho-
tericin B. While was previously registered in Norway,
flucytosine is now unregistered but can still be used on
exemption from registration in patients with cryptococcal
meningitis (33). In our study, a total of 36 isolates were
tested against flucytosine and 55.6% had MICs ]32 mg/L.
There is no EUCAST BP for flucytosine, although in
90% of these isolates, macro-colonies were found, retested
separately, and no inhibition of growth was registered.
In conclusion, MALDI-TOF MS, correctly identified in
100% of the isolates (cf. 92% by VITEK†2) and in less time
(1 h versus 18 h) than the VITEK†2, thereby representing
the most effective technique. Clustering and CCI analysis
showed variation in protein spectra between all strains
identified as C. glabrata by the MALDI-TOF MS, although
they had a signature profile detected as C. glabrata. It is
important to further understand the protein profile
Fig. 2. CCI matrix of 183 C. glabrata isolates versus reference strains presented in a heat map diagram. Strains different from C.
glabrata, expressed by dark blue lines, are marked by species names and protein profile numbers (different from sample
numbers). The dark red diagonal line represents the intersections of identical groups. The diagram illustrates variation in protein
spectra between C. glabrata and other species as well as among all isolates identified as C. glabrata in which blue and green
shades represent distance between some of the protein spectra (Maldi Biotyper Compass version 4.1).
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clustering since we observed that eight of 13 strains with
azole resistance clustered together, whereas the metabolic
profile from VITEK†2 analysis resulted in a low ID score.
If the clustering profile could indicate high-azole MICs
among the samples, it could be a rapid supplement to the
MIC determination/testing.
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